Navigation Links
Precision Optics Corporation Announces First Quarter Results and Receipt of Significant New Order
Date:11/20/2007

the Company's new products; decisions by customers to place orders for the Company's products; the risks associated with reliance on a few key customers; the Company's ability to attract and retain personnel with the necessary scientific and technical skills; the timing and completion of significant orders; the timing and amount of the Company's research and development expenditures; the timing and level of market acceptance of customers' products for which the Company supplies components; performance of the Company's vendors; the ability of the Company to control costs associated with performance under fixed price contracts; the continued availability to the Company of essential supplies, materials and services; and the other risk factors and cautionary statements listed from time to time in the Company's periodic reports filed with the Securities and Exchange Commission, including but not limited to, the Company's Annual Report on Form 10-KSB for the year ended June 30, 2007.


'/>"/>
SOURCE Precision Optics Corporation, Inc.
Copyright©2007 PR Newswire.
All rights reserved

Page: 1 2 3 4 5 6

Related medicine news :

1. Precision Optics Corporation Announces Fourth Quarter and Year End Results With Highest Revenues in Six Years
2. Varian Medical Systems to Unveil RapidArc(TM) Volumetric Arc Therapy and Other Products Designed to Speed Delivery of Precision Radiotherapy and Brachytherapy
3. New Generation Xcelodose(R)S Precision Drug Powder Micro-filling System Offers 50% Increased Throughput
4. AZoOptics.com - The A to Z of Optics Launched By AZoNetwork
5. The ScottCare Corporation Completes Acquisition of Rozinn Electronics, a Leading Manufacturer of Cardiac Diagnostic Products
6. Brooke Franchise Corporation Announces Selected July Results
7. MedThink Communications Retained by NanoBio Corporation
8. EaglePicher Corporation Completes Transaction to Sell EaglePicher Boron, LLC to Ceradyne, Inc. for $69 Million
9. Dana Corporation, Inc. Enters Into Settlement Agreement With Dana Retiree Committee
10. Sontra Medical Corporation Changes Name to Echo Therapeutics, Inc.
11. Memry Corporation Announces Fiscal Fourth Quarter and 2007 Year End Earnings Release and Conference Call
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:11/21/2008)... Kids, parents and schools need to work together t... FRIDAY, Nov. 21 (HealthDay News) -- Behavior that...cognized as bullying. , And as mounting researc... the victim, mental-health professionals, schools,...th new ways to combat this threatening behavior. ...
(Date:11/21/2008)..., HOUSTON(Nov. 21, 2008)The University of Texas He...rogram, Training Excellence in Aging Studies (TEXA...through a prestigious $2 million award from the Do...atching funds., "This will allow us to teach geri...t junior medical student to practicing physicians....
(Date:11/21/2008)... TUCSON, Ariz., Nov. 21 ...C ) today announced that Craig A. Norris, the Comp... to the Company,s Board of,Directors. Mr. Norris...2008,resignation of Steven I. Geringer and return...serve on any committee of the Board. , Mr. ...
(Date:11/21/2008)... Trials showed Banzel proved effective against Len... (HealthDay News) -- A new drug called Banzel (ruf...tment for a severe form of epilepsy called Lennox-...ation announced Friday. , The approval was base...ncluded patients ages 4 to 30. Compared to patient...
Breaking Medicine News(10 mins):Health News:Getting Tough on Bullying 2Health News:Getting Tough on Bullying 3Health News:UT Houston launches geriatric training with $3.25 million in grant, matching funds 2Health News:UT Houston launches geriatric training with $3.25 million in grant, matching funds 3Health News:UT Houston launches geriatric training with $3.25 million in grant, matching funds 4Health News:Craig A. Norris Appointed to Providence Service Corporation Board of Directors 2Health News:Craig A. Norris Appointed to Providence Service Corporation Board of Directors 3Health News:FDA Approves New Drug for Severe Epilepsy 2
...t the Shanghai Children’s Medical Center have succ...rare, well-developed third arm from a two-month-ol...t arms that had been laid across Liu Junjie's ches...is further up his shoulder. ‘We found the nerves ...
... Health Organisation has ruled out human-to-human ...esian nurses tending patients with the disease // ...he ability to spread more readily among humans. 'T...nurses provide reassuring evidence that the virus ...
... drug used to treat chronic myeloid leukemia has s...f patients with the cancer.// The National Institu...h regulates drug approvals in the UK had only want...s, but the drug has not proved itself in clinical ...
...ight is back on drugs and high life in Mumbai with...hospital, and Sahil Zarru, who is suspected to hav...arty circuit here. "Cocaine, ecstasy, acid and her...rugs,are a rage with the rich and the famous in Mu...
Other Medicine News:Health News:Drugs Part of Mumbai High Life 2
(Date:11/20/2008)... Calif., Nov. 20 Milk. It does a b...originally thought. After years of,research, scie...es found in,cow,s milk that stimulate the body,s ...ew the Multimedia News Release, go to:, http://www... While developing new cancer therapies, the chie...
(Date:11/20/2008)...Nov. 20 Clinical data from a prosp...nnual Veith Symposium shows DVT,treatment with th...us,Vascular, Inc. (Santa Clara, CA) successfully ...t 20 minutes. , This technique, called isol...ood flow more quickly and safely than current cath...
(Date:11/19/2008)...AKS, Calif., Nov. 19 Amg...ncology Company, a subsidiary of,Takeda Pharmaceu... that,enrollment in the Phase 3 MONET1 trial eval...clitaxel and carboplatin for the first-line treatm...) has been temporarily suspended,following a plan...
(Date:11/19/2008)...l., Nov. 19 Isogen, a contract dev...le filling, today announced the first,phase launc... founded to,specifically address the process, fac...ith the $2 billion highly-niched, low-volume clini...rket segment. , Companies can invest over $...
Breaking Medicine Technology:Photos: Peptides Discovered to Alleviate Chemotherapy Side Effects 2Trellis(R) Peripheral Infusion System Removes Blood Clots in Largest Reported Prospective Endovascular DVT (Deep Vein Thrombosis) Patient Series 2Trellis(R) Peripheral Infusion System Removes Blood Clots in Largest Reported Prospective Endovascular DVT (Deep Vein Thrombosis) Patient Series 3Amgen, Takeda and Millennium Provide Update on Phase 3 Trial of Motesanib in Patients With Non-Small Cell Lung Cancer 2Amgen, Takeda and Millennium Provide Update on Phase 3 Trial of Motesanib in Patients With Non-Small Cell Lung Cancer 3Amgen, Takeda and Millennium Provide Update on Phase 3 Trial of Motesanib in Patients With Non-Small Cell Lung Cancer 4Amgen, Takeda and Millennium Provide Update on Phase 3 Trial of Motesanib in Patients With Non-Small Cell Lung Cancer 5Amgen, Takeda and Millennium Provide Update on Phase 3 Trial of Motesanib in Patients With Non-Small Cell Lung Cancer 6Amgen, Takeda and Millennium Provide Update on Phase 3 Trial of Motesanib in Patients With Non-Small Cell Lung Cancer 7Isogen Launches Major New Facility to Address Global Biopharma Demand 2New Program Website Targets Jewish Children Teens and Adults Suffering from the Impact of Childhood Maltreatment 20926 1New Program Website Targets Jewish Children Teens and Adults Suffering from the Impact of Childhood Maltreatment 20926 2Ferndale and Foamix Execute License Agreement for Development of Non Steroidal Foam for Atopic Dermatitis 5760 1Ferndale and Foamix Execute License Agreement for Development of Non Steroidal Foam for Atopic Dermatitis 5760 2Chronic Stomach Inflammation Boosts Cancer Risk 20924 1Chronic Stomach Inflammation Boosts Cancer Risk 20924 2Canine Cancer Web Exclusive for Dog Owners and Lovers Presented by Morris Animal Foundation Features Colorado State and Cornell University Veterina 20919 1Canine Cancer Web Exclusive for Dog Owners and Lovers Presented by Morris Animal Foundation Features Colorado State and Cornell University Veterina 20919 2
...ieves All Key Endpoints for Both Efficacy and Safe...rstCall/ --,Indevus Pharmaceuticals, Inc. today an...inetic trial for NEBIDO (testosterone,undecanoate)...nder,development for the treatment of male hypogon...ng Pharma AG, Germany. The data,from the recently ...
... is evaluating zonisamide SR as a novel component ... June 07, 2007 /PRNewswire-FirstCall/ -- Orexigen(...ny focused on the,treatment of central nervous sys...day announced results from a Phase I trial evaluat...rietary,sustained-release (SR) formulation of zon...
Other Medicine Technology:Indevus Reports Positive Data From Phase III NEBIDO Trial 2Indevus Reports Positive Data From Phase III NEBIDO Trial 3Indevus Reports Positive Data From Phase III NEBIDO Trial 4Indevus Reports Positive Data From Phase III NEBIDO Trial 5Indevus Reports Positive Data From Phase III NEBIDO Trial 6OREXIGEN Therapeutics Announces Sustained-Release Formulation of,Zonisamide Shows Improved Tolerability When Compared to Immediate,Release Formulation 2OREXIGEN Therapeutics Announces Sustained-Release Formulation of,Zonisamide Shows Improved Tolerability When Compared to Immediate,Release Formulation 3OREXIGEN Therapeutics Announces Sustained-Release Formulation of,Zonisamide Shows Improved Tolerability When Compared to Immediate,Release Formulation 4
BD Vacutainer® PST™ Tubes contain spray-coated lithium heparin and a gel for plasma separation. They are used for plasma determinations in chemistry.
BD Vacutainer® Specialty Tubes - Sedimentation Rate Determination (SRD)
Inquire
VACUETTE paediatric tubes have decreased sample volumes and are ideal for small childrens' veins and geriatric patients.
Medicine Products: